A likely explanation of the change in clinical guidelines, which suggests an early prescription in people with diabetes at risk of DKD, is the associated drop in UACR with the use of GLP1-RAs, thereby lowering the risk of kidney failure and reducing the risk of adverse renal events. Here, GLP1R is linked to diabetic kidney disease.